Name: Name:HMN-214
Brand: Angene
SKU: AG001Z05
Rating: 90 (10 reviews)

HMN-214

CAS No.:

173529-46-9

Catalog Number:

AG001Z05

Molecular Formula:

C22H20N2O5S

Molecular Weight:

424.4696

Pack Size

Purity

Availability

Location

Price(USD)

Quantity

5mg

99%

1 week

United States

$182

- +

10mg

99%

1 week

United States

$265

- +

50mg

99%

1 week

United States

$682

- +

100mg

99%

1 week

United States

$960

- +

Product Description

Catalog Number:

AG001Z05

Chemical Name:

HMN-214

CAS Number:

173529-46-9

Molecular Formula:

C22H20N2O5S

Molecular Weight:

424.4696

MDL Number:

MFCD12756255

IUPAC Name:

N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-1-ium-4-yl)ethenyl]phenyl]acetamide

InChI:

InChI=1S/C22H20N2O5S/c1-17(25)24(30(27,28)21-11-9-20(29-2)10-12-21)22-6-4-3-5-19(22)8-7-18-13-15-23(26)16-14-18/h3-16H,1-2H3/b8-7+

InChI Key:

OCKHRKSTDPOHEN-BQYQJAHWSA-N

SMILES:

COc1ccc(cc1)S(=O)(=O)N(c1ccccc1/C=C/c1cc[n+](cc1)[O-])C(=O)C

UNII:

94E9UR0RFR

Properties

Complexity:

689

Compound Is Canonicalized:

Yes

Covalently-Bonded Unit Count:

Defined Atom Stereocenter Count:

Defined Bond Stereocenter Count:

Exact Mass:

424.109g/mol

Formal Charge:

Heavy Atom Count:

Hydrogen Bond Acceptor Count:

Hydrogen Bond Donor Count:

Isotope Atom Count:

Molecular Weight:

424.471g/mol

Monoisotopic Mass:

424.109g/mol

Rotatable Bond Count:

Topological Polar Surface Area:

97.5A^2

Undefined Atom Stereocenter Count:

Undefined Bond Stereocenter Count:

XLogP3:

2.6

Literature

Title	Journal
Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology.	The oncologist 20090601
A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors.	Clinical cancer research : an official journal of the American Association for Cancer Research 20060901
What's new in pancreatic cancer treatment pipeline?	Best practice & research. Clinical gastroenterology 20060401
In vivo antitumor activity of a novel sulfonamide, HMN-214, against human tumor xenografts in mice and the spectrum of cytotoxicity of its active metabolite, HMN-176.	Investigational new drugs 20031101

Properties